Medical/Pharmaceuticals Global News & Press Release Distribution

Bee and Honey Promote Medical and Healthcare Products via Virtual Event

GUANGZHOU, China, April 24, 2022 /PRNewswire/ -- On 16 April, with the theme of "Fight against Pandemic, Care for Each Other", the second trade promotion activity of "Discover Canton Fair with Bee and Honey" was successfully held on Canton Fair's official Facebook account. The virtual event was h...

2022-04-25 10:27 2167

Media Pooling Strategy to Increase Testing Throughput Added to Vela Diagnostics' ViroKey SARS-CoV-2 RT-PCR Test v2.0

FAIRFIELD, N.J., April 22, 2022 /PRNewswire/ -- Vela Diagnostics has announced that its ViroKey® SARS-CoV-2 RT-PCR Test v2.0 now has the additional capability to be used for pooling, using a three-in-one media pooling strategy. This FDA EUA authorized indication is authorized for use in laborator...

2022-04-22 20:00 2669

Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ

* Lunit gets greenlight to accelerate listing on the KOSDAQ market * First Korean healthcare company to receive "AA-AA" ratings in technology assessment SEOUL, South Korea, April 21, 2022 /PRNewswire/ -- Lunit, a leading medical AI provider, announced today a preliminary approval from the Kore...

2022-04-21 22:12 2361

Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion

LAGUNA HILLS, Calif. and SHANGHAI and BOCHUM, Germany, April 21, 2022 /PRNewswire/ -- Wallaby Medical ("Wallaby" or the "Company"), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced t...

2022-04-21 17:00 1822

Samsung Biologics completes full acquisition of Samsung Bioepis

* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologi...

2022-04-20 14:45 2866

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...

2022-04-20 10:27 2380

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...

2022-04-20 08:00 2294

ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

Mediscience Espoir Inc. Looking for OEM Customers, Technical Business Partners and Sales Agents for Oxygen Clathrate Hydrates and Oxygen Solutions

KAWASAKI, Japan, April 19, 2022 /PRNewswire/ -- Mediscience Espoir Inc. announced onApril 19 that it is looking for U.S. partners for oxygen clathrate hydrates and oxygen solutions based on its proprietary technology. The company obtained "Substance Patent" in the United States (US 10,913,037 B2)...

2022-04-19 14:00 2143

Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise

* The licensing deal includes an upfront payment of USD 1.63 million, and may reach up toUSD 24.4 million in milestone payments and royalties * By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive tre...

2022-04-19 09:19 2584

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic an...

2022-04-19 09:00 2216

WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC

SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the A...

2022-04-15 09:03 2943

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in mu...

2022-04-14 22:49 3626

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting

PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...

2022-04-14 20:30 3075

China Medical System (0867.HK): the Leader in Commercialization Embraces Great Industry Opportunities as Biotech Companies are Eager to Monetize Their Innovative Products

HONG KONG, April 14, 2022 /PRNewswire/ -- Recently, China Medical System ("CMS", 0867.HK) announced its annual results. After recording continuous performance growth in the difficult time of the pandemic in 2020, it once again achieved a new record high, with revenue ofRMB 8,337 million, up 20.0%...

2022-04-14 20:24 2244

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co....

2022-04-14 19:45 3549

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3...

2022-04-14 15:39 2739

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/CD73 ...

2022-04-14 15:05 2435

Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...

2022-04-14 14:54 2655

Toyobo launches major marketing initiative for Nerbridge(TM) in the U.S., setting sights on the global nerve conduit market

OSAKA, Japan, April 13, 2022 /PRNewswire/ -- Toyobo Co., Ltd. has launched a major U.S. marketing initiative for NerbridgeTM ("the product", hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held i...

2022-04-14 10:03 2149

Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr.Humphrey Gardner as Chief Medical Officer (CMO). Dr. Gardner will be responsible for leading the global product d...

2022-04-14 08:46 2332